Study of XL114 in Subjects With Non-Hodgkin's Lymphoma

Summary

This is a Phase 1, non-randomized, open-label, dose-escalation and expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical antitumor activity of XL114 administered alone orally to subjects with Non-Hodgkin's Lymphoma (NHL). The objectives of the study also include determining the recommended dose (RD) and/or maximum tolerated dose (MTD) of XL114.

Timeline

Start

2022-04-12

Primary completion

2022-11-01

Completion

2022-11-01

Outcome

Outcome not reported

Stopped: “Due to Sponsor reasons.”

Drugs

Indications